Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis

NCT00023335 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT00023335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00023335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 3
Overall status
Completed
Start date
April 30, 1995
Completion date
March 31, 2001
Enrollment
1,000
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis